Universal Ibogaine Inc.
IBOGF · OTC
7/31/2022 | 7/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Revenue | $1,071 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,071 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $409 | $63 | $0 | $0 |
| G&A Expenses | $4,568 | $3,531 | $59 | $69 |
| SG&A Expenses | $4,568 | $3,732 | $59 | $69 |
| Sales & Mktg Exp. | $0 | $201 | $0 | $0 |
| Other Operating Expenses | -$128 | $0 | $0 | $0 |
| Operating Expenses | $5,817 | $3,865 | $59 | $69 |
| Operating Income | $497 | -$3,833 | $0 | -$34 |
| % Margin | 46.4% | – | – | – |
| Other Income/Exp. Net | -$5,682 | -$19 | -$60 | -$35 |
| Pre-Tax Income | -$10,496 | -$3,867 | -$118 | -$98 |
| Tax Expense | -$60 | $15 | $59 | $0 |
| Net Income | -$10,496 | -$3,867 | -$118 | -$98 |
| % Margin | -980.2% | – | – | – |
| EPS | -0.057 | -0.031 | -0.01 | -0.01 |
| % Growth | -82.8% | -209% | 0% | – |
| EPS Diluted | -0.057 | -0.031 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 185,637 | 125,190 | 11,831 | 9,811 |
| Weighted Avg Shares Out Dil | 185,637 | 125,190 | 11,831 | 9,811 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $32 | $1 | $6 |
| Interest Expense | $68 | $15 | $0 | $0 |
| Depreciation & Amortization | $266 | $70 | $0 | $172 |
| EBITDA | -$4,607 | -$3,763 | $1 | -$34 |
| % Margin | -430.3% | – | – | – |